Scientists from the University of Toronto, the Howard Hughes Medical Institute, and the University of Minnesota have found a possible way forward in avoiding the development of cancers connected to two viruses. This comprises the virus that leads to infectious mononucleosis (more usually dubbed as the “kissing disease” or mono) that infects a number of individuals all over the globe annually.
Posted in Nature Microbiology, the study aims on how the EBV (Epstein-Barr virus) and KSHV (Kaposi’s sarcoma herpesvirus) protect themselves from getting destroyed within the human body.
“People suffering from KSHV or EBV will have the virus for their whole life,” claimed the lead author on the study and a MSTP (Medical Scientist Training Program) student at the University of Minnesota Medical School, Adam Cheng, to the media in an interview. “In most incidents, the virus will stay dormant. On the other hand, sometimes these viruses can reactivate and result in cancerous & abnormal cell development. But now, in our study, data recommends that it might be possible to hold back the virus indefinitely,” he added.
On a related note, in a main improvement in nanomedicine, a global team of researchers earlier productively programmed nanorobots in mammals for the first time that potentially contracts tumors by slashing off their supply of blood. Every nanorobot is made from a rectangular and flat DNA sheet of origami that has a size of 90 nanometers x 60 nanometers. Once bound to the surface of tumor blood vessel, the nanorobot was planned to supply its unsuspicious cargo of drug in the very center of the tumor, revealing an enzyme dubbed as thrombin that is responsible for the clotting of blood.
The nanorobots operated quickly, congregating in huge numbers to swiftly surround the tumor just hours post injection. “We have designed the first DNA robotic and completely autonomous system for a targeted and very exact drug design cancer therapy,” claimed Director and Professor at Arizona State University, Hao Yan, to the media in an interview.